The conclusion from our results is therefore that OPG autoantibodies are not credible to distinguish individuals with a reduced BMD and that the diagnostic benefit of OPG autoantibodies is too inferior to be recommended as a screening marker for osteoporosis in the clinical setting. Here, TNFRSF11B is linked to osteoporosis.